The challenge in using gene therapy approaches with Rett syndrome, is that MeCP2 is a dosage-sensitive gene and too much MeCP2 expression is toxic for brain function causing MECP2 duplication syndrome (MDS)62,63. Here, MECP2 is linked to atypical Rett syndrome.